Collagen-Binding Agent Compositions for Targeted Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for collagen-related medical conditions, such as collagenopathies, lack effective targeted delivery systems for therapeutic agents, leading to inadequate treatment outcomes and potential toxicity due to off-site effects.
Innovation Solution
Development of collagen-binding agents comprising two collagen-binding domains linked by a domain linker, which can be used to target therapeutic agents like FGF, PTH, or BMP to specific tissues, enhancing binding affinity and cross-linking of collagen molecules for improved therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If targeted delivery systems are used to deliver therapeutic agents to specific tissues, then treatment effectiveness is improved, but device complexity increases
Solution Approach 1:
The collagen-binding agent is divided into separate functional domains (collagen-binding domains linked by a domain linker) that can independently perform specific functions. This modular segmentation allows the therapeutic agent to be delivered to target tissues through the collagen-binding domains while maintaining the therapeutic function of the attached therapeutic agent, thereby improving treatment effectiveness without requiring an overly complex integrated system.
Solution Approach 2:
The collagen-binding agent serves as an intermediary molecule that bridges the therapeutic agent and the target collagen-containing tissue. The collagen-binding domains act as mediators that specifically recognize and bind to collagen, enabling targeted delivery of the therapeutic agent to the desired tissue location without direct complex interaction between the therapeutic agent and the tissue, thus improving effectiveness while managing system complexity.
2Object-affected harmful factors
If therapeutic agents are delivered to specific sites, then off-site toxicity is reduced, but manufacturing precision is required
Solution Approach 1:
The collagen-binding agent exhibits local quality through its collagen-binding domains that are specifically designed to recognize and bind to collagen structures. This localized binding capability ensures that the therapeutic agent is delivered precisely to collagen-containing tissues while minimizing distribution to non-target sites, thereby reducing off-site toxicity. The specific collagen-binding affinity provides the necessary delivery precision without requiring excessive manufacturing complexity.
3Reliability
If binding affinity to collagen is enhanced, then targeted delivery is improved, but device complexity increases
Solution Approach 1:
Multiple collagen-binding domains are merged into a single collagen-binding agent structure, linked together by a domain linker. This merging of multiple binding domains enhances the overall binding affinity to collagen through cooperative binding effects, improving targeted delivery. The domains work together as an integrated unit, achieving high affinity without requiring equally complex separate components, thus balancing effectiveness with manageable complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The collagen-binding agents provide targeted delivery of therapeutic agents to damaged or normal collagen tissues, reducing toxicity and enhancing treatment effectiveness by promoting tissue repair and growth.
Implementation Method 1
two collagen-binding domains linked by a domain linker... enhance binding affinity and cross-linking of collagen molecules
Data Source
AI summary
The invention generally relates to collagen-binding agent compositions and methods of using the same. More specifically, the invention relates in part to new collagen-binding agent compositions and methods that may be used to treat damaged collagen within tissues or used to specifically target therapeutics to tissues containing undamaged or damaged collagen.